Delta-sleep-inducing peptide (DSIP): a review.
Graf. M V MV; Kastin. A J AJ
Key Findings
- DSIP is a nonapeptide (9 amino acids) that primarily increases delta‑sleep in several species, including humans.
- Its activity follows a U‑shaped dose‑response and timing curve, meaning optimal effects require precise dosing.
- DSIP is present in the brain and peripheral tissues, and it can affect neurotransmitter levels, hormone release, circadian patterns, and drug interactions.
Practical Outcomes
- For biohackers, DSIP might be a candidate for deep‑sleep enhancement, but the lack of clear dosing guidelines and its broad physiological effects make it risky to self‑experiment. Until more human data and safety profiles are available, it’s best treated as a research‑only peptide rather than a ready‑to‑use supplement.
Summary
Delta-sleep‑inducing peptide (DSIP) is a tiny protein that can boost deep, delta‑wave sleep in animals and humans. Its effect depends on the dose and timing, showing a U‑shaped curve (too little or too much is less effective). DSIP is naturally found in the brain and blood and also seems to influence brain chemistry, hormones, circadian rhythms, and how some drugs work.
Abstract
Since the turn of the century, it has been postulated that humoral factors induce sleep. Many compounds were proposed as sleep-factors, but only two of the sleep-peptides have been purified to homogeneity and characterized, so far. One of them, DSIP, was shown to be a nonapeptide of MW 849 and to induce mainly delta-sleep in rabbits, rats, mice, and humans, whereas in cats, the effect on REM sleep was more pronounced. A U-shaped activity curve was determined for the dose as well as for the time of infusion. DSIP-like material was found by RIA and immunohistochemistry in brain and by RIA in peripheral organs of the rat as well as in plasma of several mammals. In addition to sleep, the peptide also has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.
Study Information
pubmed
1984
1984-03-01T00:00:00.000Z
10.1016/0149-7634(84)90022-8
81
127